High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the standard of care for the frontline treatment in younger patients with multiple myeloma (NDMM). [1] [2] [3] [4] The achievement of complete response (CR) or at least very good partial response (VGPR) at the end of the ASCT procedure has been one of the key markers associated with an improved outcome. [5] [6] [7] In recent years, several strategies were paralleled to increase the CR plus VGPR rate in the ASCT paradigm that included improving the induction treatment, and more recently, the consolidation and the maintenance phases post ASCT. 3, 8 The high activity shown by immunomodulatory drugs and bortezomib-based regimens before ASCT has recently led to their use as consolidation and maintenance therapies. Several studies have demonstrated the impact of VTd on response rates and progression-free survival (PFS) either as induction or consolidation regimen in NDMM; [9] [10] [11] [12] [13] however, no data are available regarding the role of VTd consolidation in the context of bortezomib-triple-based VTd induction regimen followed by a single ASCT.
We aimed to assess the efficacy and safety of VTd as consolidation therapy in the context of VTd as induction regimen, followed by a single ASCT (VTd-auto-VTd regimen). Thus, we have performed a retrospective multicentre study that has included NDMM eligible for ASCT upfront in two cohorts from 2009 to 2011 across nine IFM (Intergroupe Francophone du Myé lome) centers. We recruited all patients diagnosed in the selected period of time in these centers in order to minimize the bias of our series. The VTd-auto-VTd cohort included 121 NDMM, a regimen consisting of three induction and two consolidation cycles of VTd (bortezomib 1.3 mg/m 2 intravenously on days 1, 4, 8 and 11, thalidomide 100 mg/day orally and dexamethasone 40 mg weekly orally). All patients underwent ASCT with high-dose melphalan 200 mg/m 2 . The 96 NDMM of the second cohort (VTd-auto) completed the same VTd-auto regimen without consolidation. None of the patients received maintenance therapy across cohorts. The study was approved by the ethics committee of CHRU of Lille and was conducted in accordance with the principles of the Declaration of Helsinki. All response rates were determined according to the International Myeloma Working Group criteria. 14 In the whole study, the median age was 56 years; the sex ratio was 1.49; 50% had ISS 2 and 3; 22% had adverse FISH [t(4;14); del17p]. There was no significant difference regarding the patients' characteristics across the two groups. Overall, the ORR (overall response rate) was identical in the two cohorts at the completion of therapy, although the CR rate was significantly greater in patients who received a VTd consolidation (P ¼ 0.001) ( Table 1 ). In the two cohorts, the CR rate increased by B20% following ASCT (from 10 to 30%), and to a similar extent (from 33 to 52%) in the cohort of patients who received two additional cycles of consolidation. Of note, 28/116 (24%) patients improved the depth of response after completion of consolidation. Importantly, 23 (20%) improved the depth of response to CR among these 28 patients and 5 improved to VGPR (Table 1) . Furthermore, the patients who reached VGPR following ASCT had a significantly greater chance to reach CR following consolidation as compared with patients who did not reach VGPR, 38% versus 11.5%, respectively (P ¼ 0.018). With a median follow-up of 30 months, the relapse rate was significantly lower in the cohort VTd-auto-VTd, 25 (21%) versus 43 (45%) patients, respectively (P ¼ 0.001). The lower relapse rate consequently improved the median time to progression (TTP) in the cohort VTd-auto-VTd (P ¼ 0.005) ( Figure 1a) ; the estimated 4-year TTP was 62% and 29%, respectively, in either cohort. We further observed that patients in CR after consolidation had a greater median TTP as compared with patients who did not reach CR (Po0.0001) (Figure 1b ). In the study, nine (8%) and six patients (8%) had died in either cohort, and the expected 4-year survival was 91% and 84%, respectively (P ¼ nonsignificant (ns)). A longer follow-up might help to demonstrate greater survival end points benefit in favor of VTd consolidation.
Moreau et al. 12 have reported a 89% ORR, 74% VGPR þ CR rate, 29% CR rate after the first ASCT in the VTd arm as induction without consolidation of the phase 3 trial IFM2007-02. The relapse rate was 53% and the median PFS was 26 months (median follow-up 32 months). On the other hand, Cavo et al. 10, 11 reported 97.5% ORR, 92% VGPR þ CR rate, 61% CR rate, 39% 3-year progression and 62% estimated 5-year PFS (follow-up 43 months), respectively, in the VTd arm of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) phase 3 trial, in which VTd was given as induction (three cycles) before and consolidation (two cycles) after double ASCT upfront in myeloma. The efficacy of consolidation therapy was significantly enhanced with the addition of bortezomib to TD, as shown by the higher rates of CR (60.6% versus 46.6%) in this trial. Interestingly, we report herein a 52% CR rate with a single ASCT in our study, and the 9% difference on CR rate between the two studies may reflect the impact of the tandem ASCT. The role of tandem ASCT in the context of novel agent-based induction and consolidation is currently under evaluation both in Europe (EMN02 study-a study to compare bortezomib, melphalan and prednisone (VMP) with single or tandem ASCT followed by bortezomib, lenalidomide and dexamethasone (VRD) consolidation and lenalidomide maintenance in patients with NDMM (HO95)) and in the US (BMT CTN 0702 trial-a multicenter phase 3 trial of tandem ASCT versus the strategy of single ASCT plus consolidation therapy with lenalidomide, bortezomib and dexamethasone (RVD) or single ASCT without consolidation, lenalidomide is being used as maintenance therapy for 3 years in all arms) as part of upfront treatment of MM.
Several studies have demonstrated over the last decade that bortezomib-triplet-based induction was the standard of care for induction in MM upfront prior to ASCT.
3,4,10-13, 15 Various triplet induction regimens were reported, PAD, 16 VCd, 17 VRd 18 and VTd. As yet, no data from phase 3 randomized trials are available to draw conclusions regarding the superiority of a triplet combination over the other. Nevertheless, three prospective studies have already shown that VTd is superior to Td or bortezomib plus dexamethasone, and as such, VTd is one of the most commonly used regimens. 10, 12, 13 The achievement of CR following ASCT is the major goal of the high-dose therapy strategy. 6, 19 In this setting, previous studies have showed that consolidation treatments given generally short-term using monotherapy bortezomib 20 or lenalidomide 21 or combinations such as VTd 9,11 were able to upgrade the rates of CR. Although retrospective, our study confirms the finding of Cavo et al. 10, 11 on the role of VTd as consolidation. We further demonstrated that the triplet combination VTd as consolidation increased the CR rate by 20%, and that translated in an improved TTP.
Moreover, we found that the overall strategy consisting of VTd for three cycles prior to ASCT as induction therapy, followed by extra two cycles as consolidation after a single ASCT prepared by melphalan 200 mg/m 2 was very manageable in terms of safety profile. The additional two cycles of VTd in consolidation did not increase the toxicity. Overall, the dose reduction rate was 10% in the VTd-auto-VTd arm, including 6 and 4% that had thalidomide and bortezomib dose reduction. No death was reported in either cohort, and no discontinuation observed during consolidation. The incidence rate of grades 3 and 4 hematological EIs was 4% and 6% in either cohort, respectively (P ¼ ns). The incidence rate of grade neuropathy 3-4 was 5% and 3%, respectively, with only 1% that occurred during consolidation. We have also observed nine (9%) thromboembolic events (TE) (similar across cohorts), eight of venous type and one arterial type in the VTd-auto-VTd cohort. None of these occurred during the consolidation. No second primary malignancy was reported in our series. Overall, the most common toxicities associated to VTd included neuropathy and TE, although unrelated with consolidation, and the hematological toxicity appeared manageable.
This study demonstrated that the VTd regimen, used both as induction and consolidation, in the context of a single ASCT significantly contributed to improve clinical outcomes with an acceptable toxicity profile in NDMM. This study showed an impressive CR rate in relation to the consolidation that translated into a prolonged TTP. VTd-auto-VTd compared very favorably to the other protocols upfront, and may become in the near future a standard of care in NDMM.
CONFLICT OF INTEREST
XL, MR, MA, TF, PM, HAL and CH disclose lecture fees from Celgene and Janssen; XL discloses research support from Celgene and Janssen. The remaining authors declare no conflict of interest. Recently, novel STAT3 (Signal transducer and activator of transcription 3)-activating mutations have been identified in T-cell large granular lymphocytic (T-LGL) leukemia. However, the prevalence and specificity of STAT3 mutations in other T-cell neoplasms, in which the STAT3 pathway is also active, are unknown. As such, we sequenced STAT3 in 95 diverse T-cell malignancies including T-LGL leukemia, Sezary syndrome, anaplastic large cell lymphoma (ALCL), CD30 þ lymphoproliferative disorders in the skin and other peripheral T-cell lymphomas (PTCL) to assess the prevalence of STAT3 mutations. Such mutations are present not only in T-LGL leukemia, but also in a subset of T-cell lymphomas where CD30 is highly overexpressed: two cases of CD30 þ ALK-negative ALCL, and two cases of CD30 þ PTCL. Our results demonstrate that STAT3 mutations are not only frequent in T-LGL leukemia, but also in a subset of CD30 þ T-cell lymphomas. STAT3 is a transcription factor and oncogene that has been shown to have a critical role in cellular proliferation through cytokine and growth factor pathways. 1 While disruptive mutations in STAT3 result in hyper-IgE syndrome, 2 activating mutations have been shown to be associated with a subset of cases of T-LGL leukemia, 3 as well as chronic lymphoproliferative disorders of natural killer cells. 4 STAT3 activity has also been described as augmented in other T-cell malignancies such as ALCL 5 and Sezary syndrome. 6 Given these associations, we hypothesized that
AUTHOR CONTRIBUTIONS
Accepted article preview online 8 April 2013; advance online publication, 3 May 2013
